Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure study explores Nitroglycerin's hidden benefits

NCT ID NCT06682260

Knowledge-focused Sponsor: Copenhagen University Hospital, Hvidovre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how nitroglycerin, a medicine that relaxes blood vessels, affects heart function and urine output in 21 adults hospitalized with acute heart failure. The goal was to understand which patients might benefit most from this treatment. Results help guide future care but do not offer a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

21 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Clinical diagnosis of AHF requiring hospitalization * Systolic blood pressure ≥85 mmHg * Echocardiographic signs of cardiac dysfunction, by at least one of * Left ventricular ejection fraction ≤45% * Abnormal left ventricular filling with dilatation of the left atrium * Elevated filling pressures (systolic pulmonary artery pressure\>30, dilated vena cava inferior or E/é\>10) * Significant left-sided heart valve disease Exclusion Criteria: * Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with heart rate \> 180 or \< 40 bpm. * Retinopathy or intraocular lens implantation (contraindication to Valsalva maneuver) * Recent myocardial infarction or thromboembolic events. * Intake of sildenafil or vardenafil withing 24 h and tadalafil within 48 h. * Absolute contraindication for vasodilation using nitroglycerin as assessed by treating physician * Intravenous administration of furosemide within 2 hours of baseline measurements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aneurysm heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF)

Contacts and locations

Locations

  • Hvidovre Hospital

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.